Ndonovo Therapeutics Inc (ENDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 140 | 135 | 73 | 166 | 310 |
| Cost of Goods | 8 | 10 | 15 | 65 | 93 |
| Gross Profit | 132 | 125 | 58 | 100 | 217 |
| Operating Expenses | 3,060 | 3,400 | 2,300 | 3,078 | 4,119 |
| Operating Income | -2,919 | -3,264 | -2,227 | -2,912 | -3,809 |
| Interest Expense | 1,282 | 1,322 | 942 | 2,083 | 6,090 |
| Other Income | 11,126 | -13,889 | 63 | 4,600 | -7,415 |
| Pre-tax Income | 6,925 | -18,475 | -3,105 | -396 | -17,315 |
| Net Income Continuous | 6,925 | -18,475 | -3,105 | -396 | -17,315 |
| Net Income | $6,925 | $-18,475 | $-3,105 | $-396 | $-17,315 |
| EPS Basic Total Ops | 0.03 | -0.13 | -0.05 | -0.03 | -24.83 |
| EPS Basic Continuous Ops | 0.03 | -0.13 | -0.05 | -0.03 | -24.83 |
| EPS Diluted Total Ops | 0.01 | -0.13 | -0.05 | -0.03 | -24.83 |
| EPS Diluted Continuous Ops | 0.01 | -0.13 | -0.05 | -0.03 | -24.83 |
| EPS Diluted Before Non-Recurring Items | N/A | N/A | N/A | -0.03 | -24.83 |
| EBITDA(a) | $-2,232 | $-2,507 | $-1,434 | $-2,036 | $-918 |